Hematologist
CION Cancer Clinics
Pola-R-CHP and newer first-line options for DLBCL | CION Cancer Clinics
Pola-R-CHP is R-CHOP with vincristine replaced by polatuzumab vedotin, an antibody that carries a cell-killing medicine to lymphoma cells. In a large trial, fewer people with higher-risk DLBCL needed further treatment after it than after R-CHOP. It is not clearly better for everyone, it costs far more, and R-CHOP remains a strong choice. Here is how the decision is made. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is Pola-R-CHP and who is it offered to?
- How does Pola-R-CHP compare with R-CHOP?
- What other first-line options might your team discuss?
- How does your haematologist choose between these?
- Who is Pola-R-CHP less likely to suit?
- What do families often assume about newer treatment?
- Common questions about Pola-R-CHP
The short answer
What is Pola-R-CHP and who is it offered to?
Pola-R-CHP is R-CHOP with one medicine swapped. Vincristine, the "O", is taken out and polatuzumab vedotin is put in. It is a first treatment option for some adults with diffuse large B-cell lymphoma (DLBCL), usually those whose lymphoma carries a higher risk score.
How polatuzumab works
Polatuzumab is an antibody-drug conjugate. That means an antibody carries a strong cell-killing medicine straight to its target. The antibody finds a marker called CD79b, which sits on the surface of B cells. Once attached, the medicine is released inside the lymphoma cell.
Why it was studied in place of R-CHOP
R-CHOP has been the standard first treatment for DLBCL for many years, and many attempts to improve it had failed. A large international trial called POLARIX compared Pola-R-CHP with R-CHOP in previously untreated people. Fewer people on Pola-R-CHP needed further treatment for their lymphoma during follow-up. Regulators in several countries, including India, have since approved it for this use.
What the trial did not show
So far, the trial has not clearly shown that people live longer overall with Pola-R-CHP. The side effects were broadly similar to R-CHOP. That is why haematologists weigh it case by case rather than giving it to everyone.
What stays the same as R-CHOP
Rituximab, cyclophosphamide, doxorubicin and prednisolone are all still part of the plan. The checks before starting are the same: a heart scan, hepatitis B testing, blood tests and a PET-CT. The cycle pattern, the day-care visits and the scans partway through and at the end are also much the same. So most of what families learn about R-CHOP still applies.
This page describes the treatment in general. It cannot tell you whether it suits you, or give doses.Side by side
How does Pola-R-CHP compare with R-CHOP?
R-CHOP
Pola-R-CHP
Includes vincristine
Vincristine replaced by polatuzumab vedotin
Long track record across all risk groups
Studied mainly in people with intermediate or higher risk scores
Given in day care in repeating cycles
Given in day care on a similar cycle pattern
Numbness and tingling in hands and feet can occur
Numbness and tingling can also occur, at a broadly similar rate
Lower medicine cost, widely covered
Much higher medicine cost, and scheme cover varies
Not sure whether this applies to you?
Ask an oncologistBeyond the standard
What other first-line options might your team discuss?
Most people still start on R-CHOP or Pola-R-CHP. These other plans are chosen for particular situations.
R-mini-CHOP
R-CHOP at reduced doses for people who are very elderly or frail. It aims to control the lymphoma while keeping treatment manageable.
Usually considered for
- The very elderly
- People with several other illnesses
DA-EPOCH-R
A more intensive combination given over several days per cycle, often needing a hospital stay. It is sometimes chosen for double hit lymphoma or certain lymphomas in the chest.
It carries more infection risk and does not suit everyone.Plans without doxorubicin
If the heart is weak, doxorubicin may be replaced with another medicine, such as etoposide or gemcitabine. A heart specialist is usually involved in this decision.
Clinical trials
Trials test new medicines added to standard treatment, including bispecific antibodies and tablets that block growth signals. Ask whether a suitable trial is open and what joining would involve.
Questions to ask
- What does the trial compare?
- How often would I need to travel?
- What happens if I leave the trial?
Reaching a plan
How does your haematologist choose between these?
Confirm the diagnosis
The biopsy is checked for DLBCL, its subtype and gene changes such as MYC and BCL2. A double hit changes the conversation.
Measure the risk
The IPI score, the stage on PET-CT and the size of the largest mass show how much lymphoma there is and where.
Check your fitness
Age, heart and kidney function, diabetes, existing numbness in the feet and daily activity show what treatment you can safely manage.
Weigh access and cost
Scheme and insurance cover, travel for day care and your own priorities are discussed openly before the final plan is agreed. Bring the family member who helps make decisions, so questions are answered together.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being straight with you
Who is Pola-R-CHP less likely to suit?
Pola-R-CHP is not automatically better for everyone. For people with low-risk DLBCL, R-CHOP remains a strong choice, and the trial gave less information about them. The extra cost may not bring a clear gain in that group.
People with nerve damage already
Both plans can cause numbness or tingling in the hands and feet. If you already have this, for example from long-standing diabetes, tell your team. It may shape which medicine they choose and how closely they watch you.
People who need a different plan
Double hit lymphoma, lymphoma that started in the brain, and very frail patients were largely outside the trial. For these groups, other plans are usually considered first.
When cost blocks access
Polatuzumab is expensive. Cover under Aarogyasri, PM-JAY, CGHS, ECHS, EHS and private insurance varies, and rules change. Ask your team to check your current cover in writing. If Pola-R-CHP is not affordable, R-CHOP is a well-proven alternative, not a poor second choice.
What this page cannot tell you
It cannot tell you your outlook or which plan will work better for you. Ask your haematologist why they recommend one over the other, what they expect to gain from it in your case, and what they would do if cover or supply fell through.
Commonly believed
What do families often assume about newer treatment?
"Newer and costlier always means better."
A newer medicine is better only where trials show a meaningful gain for people like you. For some people Pola-R-CHP offers that. For others R-CHOP is just as sensible. The right plan fits the lymphoma, the person and the family's situation.
"Polatuzumab is targeted, so it is gentle."
It is still given with chemotherapy. Low white cell counts, infection, loose motions, tiredness and hair loss can all occur. The side effect pattern is broadly similar to R-CHOP.
"We should sell property to get Pola-R-CHP."
Please talk to your haematologist and a financial counsellor before making that decision. R-CHOP is an effective, widely used first treatment. Ask how much difference the change is likely to make in your specific case.
"If R-CHOP was started, it is too late to switch."
Changing plans partway through is uncommon, and there is little evidence to guide it. Ask your team, but do not stop treatment while you think about it. What matters most is completing a plan that suits you, on time, with the side effects watched closely.
Questions we are asked
Common questions about Pola-R-CHP
Is Pola-R-CHP available in India?
Yes, polatuzumab vedotin is approved in India and is used by haematologists in larger cities, including Hyderabad. Availability and supply can vary between hospitals. Your team can tell you whether it can be arranged for you, and what the approval and billing process involves.
Does Pola-R-CHP need a longer hospital stay?
Usually not. Like R-CHOP, it is given in day care, and most people go home the same day. The first cycle may take longer because the medicines are started slowly to watch for reactions. Admission may be needed if an infection develops.
Are the side effects different from R-CHOP?
In the main trial, overall side effects were broadly similar. Loose motions and fever with a low white count were reported a little more often with Pola-R-CHP. Nerve symptoms occurred with both. Tell your team about any new symptom rather than waiting for the next cycle.
Is Pola-R-CHP used if the lymphoma comes back?
Polatuzumab is also used in some relapsed settings, combined with other medicines. If it was part of your first treatment, your team will usually consider a different approach at relapse. Options such as salvage chemotherapy, transplant, CAR-T or bispecific antibodies may be discussed.
Can Pola-R-CHP be given with radiotherapy?
Yes, radiotherapy may be added after chemotherapy for a bulky mass or an area that remains active on the final PET scan. This decision is made after treatment, based on scan results. It is the same approach used with R-CHOP.
Does Aarogyasri or insurance cover polatuzumab?
Cover varies by scheme, package and policy, and changes over time. Some private insurers cover it with prior approval. Government schemes may cover lymphoma treatment packages that do not include every newer medicine. Check the current rules with your scheme and hospital billing team before starting.
Should I wait for Pola-R-CHP to be approved by my insurer?
DLBCL grows quickly, so long waits can be harmful. If approval is delayed, ask your haematologist whether starting R-CHOP is the safer course. Do not let paperwork hold up treatment for weeks without discussing it with your team.
How can I get a second opinion on first-line options?
Bring the biopsy report, any gene test results, the PET-CT and recent blood tests. CION's haematology team reviews reports, discusses cases at a tumour board and explains the reasoning behind each option. A second opinion should not delay the start of treatment.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Polatuzumab Vedotin-piiq
- National Cancer Institute — Adult Non-Hodgkin Lymphoma Treatment (PDQ) - Health Professional Version
- NICE — Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
- Leukemia & Lymphoma Society — Non-Hodgkin Lymphoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
R-CHOP: The Standard Regimen ExplainedThe standard plan Pola-R-CHP is compared againstIPI Score: Predicting DLBCL OutcomeThe risk score that shapes this choiceMYC, BCL2 and BCL6 Testing in LymphomaGene results that can point to a different planDLBCL Treatment Cost in IndiaIndicative costs and scheme cover
Talk to us
Deciding between R-CHOP and Pola-R-CHP?
Share your reports with us. CION's haematology team will explain the options, the trade-offs and what your cover allows.